BiologicalDrug
Vaxelis clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 1
- first study started
- 2022
How studies write it
Studies that test it under each name
Name
Studies by the year they started
5 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 1
- Phase 3
- 1
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 2
Sanofi Pasteur, a Sanofi Company (2) · Centre Hospitalier Universitaire Saint Pierre (1) · Merck Sharp & Dohme LLC (1) · Johns Hopkins Bloomberg School of Public Health (1)
Often tested with
Tested in the same studies.
Rotavirus Vaccines (2) · Acetaminophen (1) · DTaP-IPV-HB-PRP-T vaccine (1) · Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (1) · 13-valent pneumococcal vaccine (1) · Adacel (1) · Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (1) · Pentacel (1)
Studies
Open first, then newest update. How each study uses Vaxelis is read from its arms, and is right about nine times in ten.
Testing it · 5
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and ToddlersTerminatedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT06397768Written as Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and InfantsActive, not recruitingPhase 1/2Sanofi Pasteur, a Sanofi CompanyNCT06647407Written as DTap-HepB-IPV-Hib vaccine
- Maternal Determinants of Infant Immunity to PertussisCompletedPhase 4Centre Hospitalier Universitaire Saint PierreNCT05856396Written as Vaxelis® (Pertussis-containing vaccine)
- Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)CompletedPhase 4Merck Sharp & Dohme LLCNCT05289271Written as Vaxelis™
- Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)CompletedPhase 4Johns Hopkins Bloomberg School of Public HealthNCT04978818Written as Vaxelis
Given in every arm · 4 — Vaxelis is usual care beside what is tested
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3Sanofi Pasteur, a Sanofi CompanyNCT06736041Written as Vaxelis vaccine
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06824194Written as Vaxelis vaccine
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06824181Written as Vaxelis vaccine
- Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)CompletedPhase 3Merck Sharp & Dohme LLCNCT04016714Written as Vaxelis™
As the comparator · 1 — what is tested is compared with Vaxelis
Codes
What other systems call Vaxelis · ClinicalTrials.gg INT000656
- MeSH (NLM) C000617220VaxelisOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000617220 | Vaxelis | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.